Barclays PLC Sells 104,099 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Barclays PLC cut its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 24.3% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 323,496 shares of the company's stock after selling 104,099 shares during the quarter. Barclays PLC's holdings in Teva Pharmaceutical Industries were worth $7,129,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently modified their holdings of TEVA. FMR LLC boosted its position in shares of Teva Pharmaceutical Industries by 30.7% during the 4th quarter. FMR LLC now owns 81,983,231 shares of the company's stock valued at $1,806,910,000 after purchasing an additional 19,242,468 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd lifted its stake in Teva Pharmaceutical Industries by 12.8% during the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company's stock valued at $859,935,000 after purchasing an additional 4,418,961 shares during the last quarter. Lingotto Investment Management LLP boosted its holdings in Teva Pharmaceutical Industries by 2.6% during the fourth quarter. Lingotto Investment Management LLP now owns 27,192,388 shares of the company's stock worth $599,320,000 after buying an additional 688,862 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. boosted its holdings in Teva Pharmaceutical Industries by 2.2% during the fourth quarter. Migdal Insurance & Financial Holdings Ltd. now owns 26,035,422 shares of the company's stock worth $573,822,000 after buying an additional 569,412 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in Teva Pharmaceutical Industries by 5.6% in the fourth quarter. Geode Capital Management LLC now owns 9,281,052 shares of the company's stock worth $203,642,000 after buying an additional 489,041 shares during the last quarter. Institutional investors own 54.05% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on TEVA shares. Bank of America reduced their price objective on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating for the company in a research note on Thursday, March 6th. Piper Sandler boosted their price objective on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a report on Friday, January 17th. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Wednesday. UBS Group cut their price target on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a report on Thursday, January 30th. Finally, Barclays decreased their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a research note on Thursday, January 30th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $23.43.

Teva Pharmaceutical Industries Stock Up 1.1 %

TEVA stock traded up $0.16 during trading hours on Friday, hitting $14.88. The company's stock had a trading volume of 6,566,648 shares, compared to its average volume of 9,929,030. The company has a market capitalization of $16.87 billion, a PE ratio of -10.26, a price-to-earnings-growth ratio of 1.44 and a beta of 0.72. The stock has a 50 day moving average price of $15.23 and a two-hundred day moving average price of $17.56. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. Teva Pharmaceutical Industries Limited has a 12 month low of $12.47 and a 12 month high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. On average, equities research analysts expect that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.